Applications of Boc-(S)-3-Amino-4-(3-Benzothienyl)-Butyric Acid in Industrial Manufacturing

Boc-(S)-3-Amino-4-(3-Benzothienyl)-Butyric Acid serves as a specialized enantiopure building block required in advanced chemical synthesis, especially for active pharmaceutical ingredient (API) intermediates and peptide chemistry. Our factory-grade material supports multiple, rigorously controlled downstream processes where strict traceability, compositional precision, and production repeatability are critical to regulatory compliance and end-use performance. Below, we detail core application scenarios grounded in real-world industrial use:

1. Chiral API Intermediate Synthesis in Oncology Drug Manufacturing

Leading pharmaceutical manufacturers use this compound to construct the chiral side chain of several benzothienyl-containing kinase inhibitors. Its stereochemical integrity enables precise control over reaction chirality, facilitating production of oncology APIs with consistent optical purity, in compliance with regulatory expectations for enantiomeric excess and impurity profiling. Integration occurs at the protected amino acid incorporation stage, often within solid-phase or solution-phase peptide coupling workflows under GMP.

Industry compliance standards

• ICH Q7 (Good Manufacturing Practice for Active Pharmaceutical Ingredients)
• US FDA 21 CFR Part 211
• European Pharmacopoeia (monograph-specific if applicable)
• Active Substance Master File (ASMF) regulatory submission guidelines

Typical usage ratio

• 0.92–1.02 molar equivalents per coupling event, adjusted for reaction yield and downstream impurity specifications

Downstream process integration

• Chiral amino acid incorporation during peptide elongation for targeted benzothienyl analogues
• Used post-Boc protection group deprotection; enters amidation step for API assembly
• Subject to release and in-process QC for residual Boc content, enantiomeric purity, and trace benzothiophene breakdown products

Final product types

• Oral or injectable kinase inhibitor drug substances
• Advanced preclinical trial compounds for targeted oncology therapeutics
• Small-molecule chiral reference standards for R&D

2. Peptide Drug Development for Neurological Disorder Research

Discovery and development teams in the neuropharmaceutical sector incorporate this protected amino acid to create new peptide analogues demonstrating enhanced blood-brain barrier permeability. Its benzothienyl substitution is critical for structure-activity relationship optimization, particularly in lead optimization pipelines for central nervous system (CNS) therapeutics. Manufacturers integrate it during solid-phase peptide synthesis (SPPS) cycles, leveraging its high chemical purity for reliable chain extension and subsequent peptide folding studies.

Industry compliance standards

• ICH Q11 (Development and Manufacturing of Drug Substances)
• USP General Chapter <797> (Pharmaceutical Compounding—Sterile Preparations)
• GLP (Good Laboratory Practice) for research applications
• ISO 9001:2015 Quality Management Systems

Typical usage ratio

• 1.00 molar equivalent, with minimal excess to streamline downstream purification and peptide recovery rates

Downstream process integration

• Sequential amino acid activation and coupling during SPPS on resin-bound peptides
• Removal of Boc group prior to cyclization or amidation steps
• Integrated into analytical QC for monitoring sequence fidelity and racemization

Final product types

• Prototype neuropeptide drugs for CNS disorder research
• Synthetic peptide libraries with benzothienyl side chains
• Preclinical neuroactive peptide probes

3. Custom Pharmaceutical Contract Manufacturing (CDMO/CMO) for Clinical Trial Materials

Specialty contract manufacturers source this protected intermediate for rapid synthesis campaigns that support early-phase clinical studies. Custom peptide and small-molecule assemblies rely on the ability to tightly control input stoichiometry and minimize batch-to-batch variability. The compound's incorporation at designated peptide or drug intermediate nodes drives predictable process scale-up and compliance documentation during investigational new drug (IND) enabling runs.

Industry compliance standards

• EU GMP Part II (for APIs)
• FDA cGMP (21 CFR 210/211)
• Annex 1 (Manufacture of Sterile Medicinal Products, if sterile production is used)
• Client-specific analytical method validation protocols

Typical usage ratio

• 0.95–1.05 molar equivalents per coupling step, fine-tuned based on reaction scale and impurity profile requirements for clinical grade material

Downstream process integration

• Intermediate integration during multi-step batch synthesis for advanced clinical candidates
• Process analytical technology (PAT) used at this reaction node for real-time yield and enantiomeric excess monitoring
• Material tracking embedded in ERP and batch record systems

Final product types

• Clinical trial supply batches of peptide or small-molecule drug substances (Phase I/II studies)
• Regulatory reference samples for IND submissions
• Outsourced API intermediates for sponsor qualification

4. High-Purity Reference Material Production for Analytical Laboratories

Major reference standard suppliers use this amino acid as a primary precursor when manufacturing ultra-high purity calibration and assay standards for use in HPLC, LC-MS and chiral chromatography applications. Laboratories require reference materials with certified assay, well-documented impurity levels, and traceability, particularly for method development in regulated environments. The raw material undergoes stringent documentation and segregated handling protocols from intake through purification and homogeneity assessment steps.

Industry compliance standards

• ISO/IEC 17025 (Testing and Calibration Laboratories)
• Pharmacopeial standard reference material programs (USP, EP, JP as applicable)
• ISO Guide 34/ISO 17034 (Reference Material Producers)
• GLP for analytical standard production

Typical usage ratio

• 100% usage as a starting material; no substitutions permitted for reference-grade syntheses due to traceability requirements

Downstream process integration

• Direct use as primary input in certified reference material batch synthesis
• Purification via preparative chiral HPLC and subsequent lyophilization
• Identity confirmation and impurity profiling by NMR, MS, and elemental analysis

Final product types

• Certified chiral reference standard vials for analytical laboratories
• Calibration solutions for HPLC/UPLC and LC-MS analysis
• Traceable impurity markers for pharmaceutical quality control